Form 4: Xtant Medical Holdings Director McNamara Acquires Shares Through Deferred Stock Unit Award

Director Robert McNamara acquired 162,162 shares of Xtant Medical Holdings through a deferred stock unit award, subject to continued service as a director.

Summary

• Robert McNamara, a director of Xtant Medical Holdings, Inc., acquired 162,162 shares of common stock on August 15, 2024, through a deferred stock unit award.
• The shares were granted under the company's 2023 Equity Incentive Plan and vest on August 15, 2025, contingent upon McNamara remaining a director through the vesting date.
• Following the transaction, McNamara beneficially owns 754,151 shares of Xtant Medical Holdings, Inc., which includes 307,342 shares issuable upon settlement of deferred stock units granted under the 2023 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's stock acquisition through a pre-existing equity plan. It doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of shares by a director signals confidence in the company's future.
• The vesting condition of continued service aligns the director's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the shares is contingent on the director's continued service, implying a commitment to the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the medical device industry. Monitoring such transactions can provide insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's continued commitment to the company.
• Employees may view this as a positive sign of leadership's confidence in the company's future.

Key Dates